US › Healthcare

BioXcel Therapeutics Inc (BTAI)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$0.86+1.53%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$206,000
Revenue YoY
+22.6%
Net profit
$-12.7M
Profit YoY
-75.0%
EPS
$-0.54
EPS estimate
$-0.48
Net margin
-6,160.7%

EPS came in at -0.54 against a street estimate of -0.48 — a miss of 12.5%.

Key statistics

Market cap
$24.9M
Forward P/E
0.0
P/B
27.50
Book value
$-3.90
EPS (TTM)
$-4.81
52-week high
$8.08
52-week low
$0.74
50-day MA
$1.08
200-day MA
$1.51
Beta
0.27

Analyst view

Analysts rate BioXcel Therapeutics Inc a buy (2 buy, 0 hold, 1 sell out of 3) with an average price target of $14.00.

Shareholding

Insiders
3.65%
Institutions
18.72%

Largest institutional holders

FundStake
Millennium Management LLC6.27%
Armistice Capital, LLC6.19%
Oaktree Capital Management LLC0.78%
Geode Capital Management, LLC0.75%
Vanguard Capital Management, LLC0.67%
JONES FINANCIAL COMPANIES LLLP0.43%
Man Group PLC0.31%
State Street Corp0.30%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for BioXcel Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.